Topics

Human medicines European public assessment report (EPAR): Besponsa, inotuzumab ozogamicin, Revision: 2, Authorised

09:10 EST 1 Feb 2018 | European Medicines Agency
This article has expired, however you can still download the PDF.
Preview:
...

Other Sources for this Article

Original Article: Human medicines European public assessment report (EPAR): Besponsa, inotuzumab ozogamicin, Revision: 2, Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Besponsa, inotuzumab ozogamicin, Revision: 2, Authorised"

Quick Search